{"id":70781,"date":"2026-05-12T11:03:24","date_gmt":"2026-05-12T11:03:24","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&p=70781"},"modified":"2026-05-21T07:14:09","modified_gmt":"2026-05-21T07:14:09","slug":"hgh-fragment-176-191","status":"publish","type":"product","link":"https:\/\/medsbase.com\/nl\/hgh-fragment-176-191\/","title":{"rendered":"HGH Fragment 176-191"},"content":{"rendered":"

<\/p>\n

\n

Quick Answer \u2014 What is HGH Fragment 176-191?<\/h3>\n

HGH Fragment 176-191<\/strong> is a 16-amino-acid synthetic peptide corresponding to the C-terminal residues 176\u2013191 of human growth hormone<\/a>. In published research it retains the lipolytic (fat-mobilising) and glucose-modulating activity of the parent HGH molecule but lacks GH-receptor binding affinity and therefore does not activate IGF-1 production, chondrocyte signalling, or any of the growth-promoting effects of full-length HGH. Sequence: YLRIVQCRSVEGSCGF. Supplied in 5\u201315\u00a0mg lyophilized vials for laboratory research use only.<\/p>\n<\/div>\n

Wat u krijgt bij MedsBase:<\/strong> Onderzoekskwaliteit lyofiliseerde peptiden \u00b7 HPLC \u226599% zuiverheid (COA op aanvraag) \u00b7 Discrete temperatuurstabiele verpakking \u00b7 Wereldwijde peptidekoerier \u00b7 1.400+ geverifieerd klantbeoordelingen<\/a><\/div>\n

\ud83d\udce6 Elke bestelling is gedekt door onze Reshipment Assurance Policy<\/strong><\/a> \u2014 als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Specificatie<\/th>\nDetail<\/th>\n<\/tr>\n<\/thead>\n
CAS-nummer<\/strong><\/td>\n66004-57-7 (HGH Fragment 176-191; distinct from AOD9604 CAS 221231-10-9)<\/td>\n<\/tr>\n
Molecuulformule<\/strong><\/td>\nC78<\/sub>H125<\/sub>N23<\/sub>O23<\/sub>S2<\/sub><\/td>\n<\/tr>\n
Moleculair gewicht<\/strong><\/td>\n1817.06 Da<\/td>\n<\/tr>\n
Sequentie<\/strong><\/td>\nTyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (YLRIVQCRSVEGSCGF, 16 amino acids; positions 176\u2013191 of native human growth hormone, retaining the Cys182\u2013Cys189 disulfide bridge of the parent)<\/td>\n<\/tr>\n
Form<\/strong><\/td>\nLyofiliseerd poeder (wit tot off-white)<\/td>\n<\/tr>\n
Zuiverheid<\/strong><\/td>\n\u226599% (HPLC geverifieerd, COA op aanvraag)<\/td>\n<\/tr>\n
Opslag<\/strong><\/td>\nLyofiliseerd: 2\u20138 \u00b0C (koelkast) voor werkvoorraad; \u221220 \u00b0C voor langdurige opslag van ongeopende flesjes. Gereconstitueerd: 2\u20138 \u00b0C, gebruik binnen ~30 dagen. Bescherm tegen licht. Vries de gereconstitueerde oplossing niet in en ontdooi deze niet.<\/td>\n<\/tr>\n
Oplosbaarheid<\/strong><\/td>\nBacteriostatisch water (aanbevolen) of steriel water voor kortere gebruiksperioden<\/td>\n<\/tr>\n
Onderzoeksgebruik<\/strong><\/td>\nAlleen voor laboratoriumonderzoek. Niet voor humaan of veterinair diagnostisch of therapeutisch gebruik.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/p>\n

What Is HGH Fragment 176-191?<\/h2>\n

HGH Fragment 176-191<\/strong> is a 16-amino-acid synthetic peptide corresponding to the C-terminal residues 176 through 191 of native human growth hormone. The fragment was identified through structure-function research on HGH conducted at Monash University in the 1990s, when investigators systematically truncated and modified the HGH molecule to map the regions responsible for each of its multiple biological activities. The 176-191 region proved to retain the lipolytic (fat-mobilising) and antilipogenic activity of full-length HGH while completely losing the GH-receptor-binding domain that resides in the N-terminal portion of the parent molecule.<\/p>\n

The well-characterised sequence is YLRIVQCRSVEGSCGF with the native Cys182\u2013Cys189 intramolecular disulfide bridge preserved (these become Cys7\u2013Cys14 within the fragment numbering). Molecular weight 1817.06\u00a0Da, empirical formula C78<\/sub>H125<\/sub>N23<\/sub>O23<\/sub>S2<\/sub>. HGH Fragment 176-191 is structurally and pharmacologically distinct from AOD9604<\/strong> \u2014 an analog developed by Metabolic Pharmaceuticals that adds an N-terminal tyrosine substitution (creating Tyr-HGH 177-191) and modifies the disulfide bridge. AOD9604 has its own CAS (221231-10-9) and pharmacological profile and should not be confused with the unmodified 176-191 fragment supplied here.<\/p>\n

HGH Fragment 176-191 is supplied as a high-purity lyophilized powder for reconstitution with bacteriostatic water. The fragment is niet goedgekeurd<\/strong> by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. The research-grade HGH Fragment 176-191 sold here is supplied uitsluitend voor laboratoriumonderzoek<\/strong> and is not intended for human or veterinary administration. For the full-length parent molecule, see our HGH 191AA<\/a> product page.<\/p>\n

Mechanism of Action \u2014 Lipolytic Activity Without GH Receptor Binding<\/h2>\n

What makes HGH Fragment 176-191 mechanistically distinctive is the decoupling of lipolysis from growth-axis signalling<\/strong> \u2014 one of the cleanest examples of structure-function dissection in peptide pharmacology research:<\/p>\n